相关实验视频
Updated: Jul 17, 2025

In Vivo Inhibition of MicroRNA to Decrease Tumor Growth in Mice
Published on: August 23, 2019
通过与miR-146a-3p的相互作用,PIWIL2可以抑制甲状腺癌的进展
Xiaoxiao Lu1, Qingyun Zhu2, Hong Du3
1Department of Endocrinology and Metabolism, Punan Hospital, Pudong New Area, Shanghai, 200125, China.
皮维尔2通过海绵化miR-146a-3p来抑制甲状腺癌 (TC) 的进展. 这种相互作用为TC治疗提供了新的治疗策略,包括管理复发和转移.
科学领域:
- 分子生物学分子生物学
- 在瘤学瘤学.
- 基因规则 基因规则
背景情况:
- 传统上与通过piRNA的繁殖相关的PIWIL2,因其在癌症中的作用越来越受认可.
- 了解PIWIL2在甲状腺癌 (TC) 中的功能对于开发向疗法至关重要.
研究的目的:
- 研究PIWIL2的作用及其与miR-146a-3p在甲状腺癌进展中的相互作用.
- 在TC患者中确定PIWIL2和miR-146a-3p的临床意义.
主要方法:
- 在TC组织和细胞系中分析PIWIL2和miR-146a-3p的表达.
- 在体外实验中评估细胞增殖,细胞循环,细胞亡,迁移和侵入PIWIL2/miR-146a-3p调制的实验.
- 在体内异种移植模型验证miR-146a-3p/PIWIL2轴对TC进展的影响.
主要成果:
- 在TC组织中,PIWIL2和miR-146a-3p呈现逆表达,PIWIL2作为miR-146a-3p的海绵.
- 对PIWIL2的上调抑制了TC细胞增殖和转移,同时促进了细胞亡;miR-146a-3p具有相反的效果.
- 在体内研究证实,PIWIL2过度表达抑制了TC进展,miR-146a-3p可逆的效果,PIWIL2抑制促进了TC,miR-146a-3p抑制可逆.
结论:
- 皮维尔2通过海绵化miR-146a-3p.p.抑制甲状腺癌的进展.
- 这个轴为TC的早期治疗,复发和转移提供了潜在的治疗目标.
更多相关视频
09:40Author Spotlight: Unveiling the Role of TMOD3 in Platinum Resistance and Immune Infiltration in Ovarian Cancer
Published on: August 2, 2024
13:18Network Pharmacology Prediction and Experimental Validation of Trichosanthes-Fritillaria thunbergii Action Mechanism Against Lung Adenocarcinoma
Published on: March 3, 2023
相关概念视频
Abnormal Proliferation
MicroRNAs
mTOR Signaling and Cancer Progression
The mTOR pathway or the...
PI3K/mTOR/AKT Signaling Pathway
Synthesis and Regulation of Thyroid Hormones
Upon reaching the thyroid gland, TSH stimulates the follicular cells' active uptake of iodide ions from the blood. The ions diffuse to the apical surface of the cells and are oxidized to iodine. The...
Interactions Between Signaling Pathways
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...